Bauer W R, Neubauer S, Obitz G, Ertl G
Medizinische Universitätsklinik, Würzburg, Germany.
J Mol Cell Cardiol. 1994 Apr;26(4):527-37. doi: 10.1006/jmcc.1994.1063.
The coronary vascular effect of atrial natriuretic peptide is controversial: Coronary vasodilator as well as constrictor effects have been reported. The controversy may originate from interference of atrial natriuretic peptide with the renin-angiotensin system and/or tachyphylaxis of the effect of atrial natriuretic peptide. The effect of alpha-human atrial natriuretic peptide bolus application on changes of coronary flow was examined in the isolated, constant-pressure perfused rat heart. Six groups were considered: (1) control group; groups in which the renin-angiotensin system was modulated by pretreatment with continuous infusion of: (2) angiotensin II, (3) the angiotensin converting enzyme inhibitor captopril (4) the angiotensin II receptor blocker saralasin; and groups in which tachyphylaxis was examined by pretreatment with ANP, (5) as continuous infusion and (6) as bolus application. First, in control hearts, dose-response curves were obtained for single ANP dosages of 1-100 nmol. The effect of high dosages (40 and 100 nmol) was biphasic, with an initial vasodilator and subsequent long-lasting vasoconstrictor component. Hearts in which coronary flow was reduced by approximately 18% through continuous angiotensin II infusion showed an enhanced early vasodilator response after ANP administration, whereas the vasoconstrictor effect was no longer observable. Angiotensin converting enzyme inhibition and angiotensin II receptor blockade reduced the vasodilator effect of ANP. In addition, saralasin nearly abolished ANP-induced vasoconstriction, whereas vasoconstriction was unaltered by pretreatment with captopril. Captopril or saralasin alone did not change coronary flow, heart rate and left ventricular developed pressure. In groups (5) and (6). ANP bolus application showed significantly reduced vasomotor activity. We conclude that in the isolated rat heart. ANP has a biphasic effect with early vasodilation and late vasoconstriction. Both effects can be modulated by inhibition of the renin-angiotensin system at different levels indicating that vasomotor ANP effects result from interaction of ANP with the local renin-angiotensin system. ANP effects can be markedly reduced by tachyphylaxis.
已有报道称其具有冠状动脉舒张和收缩作用。这种争议可能源于心房利钠肽对肾素 - 血管紧张素系统的干扰和/或心房利钠肽效应的快速耐受性。在离体、恒压灌注的大鼠心脏中,研究了静脉注射α - 人心房利钠肽对冠状动脉血流变化的影响。实验分为六组:(1)对照组;通过持续输注进行预处理以调节肾素 - 血管紧张素系统的组:(2)血管紧张素II,(3)血管紧张素转换酶抑制剂卡托普利,(4)血管紧张素II受体阻滞剂沙拉新;以及通过心房利钠肽预处理来研究快速耐受性的组,(5)持续输注和(6)静脉注射。首先,在对照心脏中,获得了1 - 100 nmol单一心房利钠肽剂量的剂量 - 反应曲线。高剂量(40和100 nmol)的作用是双相的,最初为血管舒张,随后是持久的血管收缩成分。通过持续输注血管紧张素II使冠状动脉血流减少约18%的心脏,在给予心房利钠肽后早期血管舒张反应增强,而血管收缩作用不再明显。血管紧张素转换酶抑制和血管紧张素II受体阻滞降低了心房利钠肽的血管舒张作用。此外,沙拉新几乎消除了心房利钠肽诱导的血管收缩,而卡托普利预处理对血管收缩没有影响。单独使用卡托普利或沙拉新不会改变冠状动脉血流、心率和左心室舒张末压。在(5)和(6)组中,静脉注射心房利钠肽显示血管运动活性显著降低。我们得出结论,在离体大鼠心脏中,心房利钠肽具有双相作用,早期血管舒张和晚期血管收缩。这两种作用都可以通过在不同水平抑制肾素 - 血管紧张素系统来调节,表明心房利钠肽的血管运动作用是由心房利钠肽与局部肾素 - 血管紧张素系统相互作用产生的。快速耐受性可使心房利钠肽的作用显著降低。